Overall, these data indicate that SAMD9 stimulates GSK3β ubiquitination by enhancing the MYH9/TRAF6/GSK3β interaction, thereby activating β‐catenin signaling and ultimately upregulating MYH9 expression and promoting ESCC progression. Here, TRAF6 is linked to esophageal squamous cell carcinoma.